Vertex Pharmaceuticals and Mitsubishi Pharma sign agreement for development and commercialisation of the oral HCV protease inhibitor VX-950 in Japan and Far East countries.

(From Chemical Business NewsBase - Press Release)

Vertex Pharmaceuticals Inc (Vertex) and Mitsubishi Pharma Corp (Mitsubishi) have signed an agreement to develop and commercialise VX-950, Vertex's investigational oral protease inhibitor for the treatment of hepatitis C virus (HCV) infection, in Japan and certain Far East countries. As part of the agreement, Mitsubishi will make pre-commercial payments to Vertex to support clinical development of VX-950. Additionally, Mitsubishi will pay royalties to Vertex on commercial sales of VX-950 in Mitsubishi's territories. Vertex will retain exclusive development and marketing rights to VX-950 in the rest of the world, …